The Future of Real-World Evidence (RWE) in Post-Market Clinical Research
The Future of Real-World Evidence (RWE) in Post-Market Clinical Research
13 Jul 2026All episodes
Biomarkers in Clinical Trials: Accelerating Oncology and Rare Disease Drug Development
Biomarker-driven clinical trials dramatically increase the probability of regulatory success. Learn how biopharma sponsors leverage companion diagnostics to accelerate oncology and rare disease development.
13 Jul 2026
Building a Winning Clinical Development Plan (CDP) for Investor Readiness
Securing Series A or B biotech funding requires more than brilliant science. Learn how to architect a Clinical Development Plan (CDP) that aligns regulatory strategy with investor value inflection points.
13 Jul 2026
The Role of AI and Predictive Analytics in Optimizing Clinical Trial Design
Artificial Intelligence is fundamentally rewiring clinical research. Discover how biopharma sponsors are leveraging predictive analytics, digital twins, and robust IT architecture to optimize protocol design and slash trial timelines.
13 Jul 2026
Diversity in Clinical Trials: Regulatory Mandates, FDA Guidance, and Strategic Advantages
Clinical trial diversity is no longer an option. Explore how FDA mandates like FDORA are reshaping regulatory strategy, and how biopharma sponsors can turn compliance into a strategic commercial advantage.
13 Jul 2026
Site Selection Strategies: Identifying and Partnering with High-Performing Clinical Trial Sites
Clinical trial site selection is a high-stakes decision. Learn how modern biopharma sponsors use data-driven strategies to identify, activate, and partner with high-performing sites
13 Jul 2026
Navigating Regulatory Strategy and Vendor Selection in Phase I/II Trials
Transitioning from preclinical to Phase I/II clinical trials is biopharma’s highest-risk inflection point. Learn the regulatory and vendor selection strategies that protect your asset
13 Jul 2026
Risk-Based Quality Management (RBQM): A Strategic Approach for Clinical Sponsors
Transitioning from 100% Source Data Verification to Risk-Based Quality Management (RBQM) is a regulatory mandate and a financial imperative. Discover how biopharma sponsors are implementing RBQM in 2026
13 Jul 2026
The Hidden Costs of Clinical Trial Delays and How Strategic BD Prevents Them
Clinical trial delays cost biopharma millions in direct expenses and lost commercial revenue. Learn how strategic Business Development (BD) prevents these catastrophic bottlenecks.
13 Jul 2026
Mastering Patient Recruitment: Overcoming the Biggest Bottleneck in Clinical Research
Up to 85% of clinical trials fail to meet enrollment timelines. Discover data-driven strategies, AI tools, and predictive modeling to overcome the patient recruitment bottleneck in 2026
13 Jul 2026
Decentralized Clinical Trials (DCTs): ROI, Realities, and Implementation Strategies for Sponsors
When the global pandemic forced the clinical research industry into an overnight digital transformation, Decentralized Clinical Trials (DCTs) were heralded as the ultimate savior of drug development. The industry buzzed with utopian predictions of entirely "site-less" trials, where patients would participate exclusively from their living rooms, and
13 Jul 2026
Functional Service Provider (FSP) vs. Full-Service Outsourcing: Which Model Wins in 2026?
Choosing between an FSP and Full-Service CRO model dictates your clinical trial's cost, control, and timeline. Discover which outsourcing strategy wins for biopharma in 2026
13 Jul 2026
Agentic AI in Clinical Trials: Moving Beyond Automation to Protocol Design
Discover how agentic AI is moving beyond simple automation to actively design clinical trial protocols, reduce operational bottlenecks, and reshape CRO efficiency in 2026.
14 Jun 2026
The Strategic Guide to Selecting the Right CRO for Early-Stage Biotech
Choosing the right Contract Research Organization (CRO) is a make-or-break decision for biotech startups. Learn how to navigate RFPs, bid defenses, and vendor selection to protect your clinical assets
04 Feb 2026